Capital Research Global Investors Sells 28,714 Shares of IQVIA Holdings Inc. $IQV

Capital Research Global Investors lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.2% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 872,634 shares of the medical research company’s stock after selling 28,714 shares during the period. Capital Research Global Investors’ holdings in IQVIA were worth $196,718,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Eubel Brady & Suttman Asset Management Inc. bought a new position in IQVIA in the 3rd quarter valued at $14,278,000. Eagle Rock Investment Company LLC raised its position in IQVIA by 33.6% in the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after purchasing an additional 11,657 shares during the last quarter. OPTIMAS CAPITAL Ltd bought a new position in IQVIA in the 3rd quarter valued at $4,008,000. EDENTREE ASSET MANAGEMENT Ltd bought a new position in IQVIA in the 3rd quarter valued at $7,368,000. Finally, AMG National Trust Bank bought a new position in IQVIA in the 3rd quarter valued at $3,713,000. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on IQV shares. Royal Bank Of Canada started coverage on IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective for the company. Weiss Ratings downgraded IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price for the company in a research report on Friday, March 6th. Morgan Stanley set a $225.00 target price on IQVIA in a research report on Thursday, May 7th. Finally, TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and boosted their target price for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $224.13.

IQVIA Trading Up 0.1%

IQV stock opened at $183.64 on Tuesday. The company has a market cap of $30.65 billion, a P/E ratio of 22.76, a PEG ratio of 1.57 and a beta of 1.21. IQVIA Holdings Inc. has a twelve month low of $151.58 and a twelve month high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The business has a fifty day moving average of $172.42 and a 200-day moving average of $194.55.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the previous year, the company posted $2.70 earnings per share. The firm’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA announced that its board has approved a share repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.